Literature DB >> 28204563

Incidence rate for bladder cancer in Japanese in Japan and in the United States from the Cancer Incidence in Five Continents.

Tomohiro Matsuda1, Ayako Okuyama1.   

Abstract

Entities:  

Year:  2017        PMID： 28204563     DOI： 10.1093/jjco/hyx017

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN： 0368-2811            Impact factor:   3.019


× No keyword cloud information.
  8 in total

1.  Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor.

Authors:  Ken Wakai; Takanobu Utsumi; Kei Yoneda; Ryo Oka; Takumi Endo; Masashi Yano; Masaaki Fujimura; Naoto Kamiya; Nobuyuki Sekita; Kazuo Mikami; Isamu Sugano; Nobuyuki Hiruta; Hiroyoshi Suzuki
Journal:  Int J Clin Oncol       Date:  2018-05-26       Impact factor: 3.402

2.  Preoperative Clinical Predictors of Lymphovascular Invasion of Bladder Tumors at Transurethral Resection Pathology.

Authors:  Kei Yoneda; Takanobu Utsumi; Ken Wakai; Ryo Oka; Takumi Endo; Masashi Yano; Naoto Kamiya; Nobuyuki Hiruta; Hiroyoshi Suzuki
Journal:  Curr Urol       Date:  2020-10-13

Review 3.  Urinary extracellular vesicles: a rising star in bladder cancer management.

Authors:  Fumihiko Urabe; Takahiro Kimura; Kagenori Ito; Yusuke Yamamoto; Shunsuke Tsuzuki; Jun Miki; Takahiro Ochiya; Shin Egawa
Journal:  Transl Androl Urol       Date:  2021-04

4.  Impact of Lymphovascular Invasion on Prognosis in the Patients with Bladder Cancer-Comparison of Transurethral Resection and Radical Cystectomy.

Authors:  Kei Yoneda; Naoto Kamiya; Takanobu Utsumi; Ken Wakai; Ryo Oka; Takumi Endo; Masashi Yano; Nobuyuki Hiruta; Tomohiko Ichikawa; Hiroyoshi Suzuki
Journal:  Diagnostics (Basel)       Date:  2021-02-04

5.  Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.

Authors:  Hiroyuki Nishiyama; Yoshiaki Yamamoto; Naoto Sassa; Kazuo Nishimura; Kiyohide Fujimoto; Satoshi Fukasawa; Minato Yokoyama; Hideki Enokida; Kenichi Takahashi; Yoshinobu Tanaka; Kentaro Imai; Takashi Shimamoto; Rodolfo Perini; Tara Frenkl; Dean Bajorin; Joaquim Bellmunt
Journal:  Int J Clin Oncol       Date:  2019-11-15       Impact factor: 3.402

6.  Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.

Authors:  Yoshihiko Tomita; Yoshiaki Yamamoto; Norihiko Tsuchiya; Hiroomi Kanayama; Masatoshi Eto; Hideaki Miyake; Thomas Powles; Mizuki Yoshida; Yuichiro Koide; Yoshiko Umeyama; Alessandra di Pietro; Hirotsugu Uemura
Journal:  Int J Clin Oncol       Date:  2022-01-01       Impact factor: 3.402

7.  The Clinical Relevance of Fragile Histidine Triad Protein (FHIT) in Patients with Bladder Cancer.

Authors:  Xiao-Ping Liu; Xiao-Hong Yin; Xin-Hui Yan; Xian-Tao Zeng; Xing-Huan Wang
Journal:  Med Sci Monit       Date:  2018-05-12

8.  TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer.

Authors:  Quoc Thang Pham; Daiki Taniyama; Shintaro Akabane; Kenji Harada; Takashi Babasaki; Yohei Sekino; Tetsuraro Hayashi; Naoya Sakamoto; Kazuhiro Sentani; Naohide Oue; Wataru Yasui
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.